Jim Tananbaum, M.D., is the founder and chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm with approximately $3.5 billion in assets under management. Tananbaum has been a thought partner for impactful and fast-growing companies, including 10x Genomics, Amerigroup, and Jazz Pharmaceuticals.

Tananbaum’s career in healthcare investment spans more than three decades. He has founded and led multiple successful companies, including GelTex Pharmaceuticals, which brought two drugs to market and was acquired for $1.4 billion, and Theravance Inc., which has a market capitalization exceeding $4 billion. Tananbaum holds an M.D. from Harvard University, an M.B.A. from Harvard while playing rugby, and a B.S. and B.S.E.E. in applied math and electrical engineering/computer science from Yale University.